Treatment and delay of onset of synucleinopathic and amyloidogenic disease

US7919088B2 · kind B2 · utility

Assignees

• Elan Pharmaceuticals, Inc. · US
• The Regents of the University of California · US

Inventors

• Dale B. Schenk · Burlingame, US
• Kate Dora Games · Belmont, US
• Manuel J. Buttini · Emeryville, US
• Tamie J. Chilcote · San Francisco, US
• Edward Rockenstein · San Diego, US
• Eliezar Masliah · San Diego, US

Key dates

• Filing date: Aug 20, 2007
• Grant date: Apr 5, 2011
• Expiry date: Aug 20, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.